A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgG+ hybridomas in comparison to its recombinant allergen-drug conjugate.

Saved in:
Bibliographic Details
Title: A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgG+ hybridomas in comparison to its recombinant allergen-drug conjugate.
Authors: Daramola AK; South African Research Chair in Cancer Biotechnology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Medical Biotechnology & Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Akinrinmade OA; South African Research Chair in Cancer Biotechnology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Medical Biotechnology & Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA., Fajemisin EA; South African Research Chair in Cancer Biotechnology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Medical Biotechnology & Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Naran K; South African Research Chair in Cancer Biotechnology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Medical Biotechnology & Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Mthembu N; Division of Immunology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Hadebe S; Division of Immunology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Brombacher F; Division of Immunology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; International Centre for Genetic Engineering and Biotechnology (ICGEB) and Institute of Infectious Diseases and Molecular Medicine (IDM), Division of Immunology, Faculty of Health Sciences, University of Cape Town, South Africa.; Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Diseases and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, South Africa., Huysamen AM; Department of Chemistry, Faculty of Sciences, University of Cape Town, Cape Town, South Africa., Fadeyi OE; Department of Chemistry, Faculty of Sciences, University of Cape Town, Cape Town, South Africa., Hunter R; Department of Chemistry, Faculty of Sciences, University of Cape Town, Cape Town, South Africa., Barth S; South African Research Chair in Cancer Biotechnology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Medical Biotechnology & Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Source: Immunotherapy advances [Immunother Adv] 2022 Dec 06; Vol. 3 (1), pp. ltac023. Date of Electronic Publication: 2022 Dec 06 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101776979 Publication Model: eCollection Cited Medium: Internet ISSN: 2732-4303 (Electronic) Linking ISSN: 27324303 NLM ISO Abbreviation: Immunother Adv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2732-4303
DOI:10.1093/immadv/ltac023